Gene info: ID 2263

Gene: FGFR2

GENE ID: 2263

Synonyms: BBDS|BEK|BFR-1|CD332|CEK3|CFD1|ECT1|JWS|K-SAM|KGFR|TK14|TK25

Description: fibroblast growth factor receptor 2

Gene type: protein-coding

Location: 10q26.13

dbXrefs: Ensembl:ENSG00000066468 MIM:176943 Vega:OTTHUMG00000019175 UniprotKB:P21802

RefSeq: NG_012449.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 12

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 4.736e-1 (AD) 8.098e-1 (ND)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg15598650	chr10:123260333	FGFR2	Gene body	4.214e-4	Alcohol use disorders	26763658
cg10314760	chr10:123353654	FGFR2	Promoter	6.343e-4	Alcohol use disorders	26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MTMR10	0.938
GPRC5B	0.89
PMP22	0.887
MAL	0.883
QKI	0.879
PREX1	0.869
ZHX2	0.868
PHLPP1	0.865
EFHD1	0.862
MYO6	0.861

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PRSS12	-0.443
MCHR1	-0.428
RTP1	-0.421
TWIST2	-0.42
DPYS	-0.417
KCNH5	-0.417
PAQR9	-0.416
PTGIS	-0.408
HS6ST3	-0.407
TPBG	-0.405

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00039	Palifermin	BiotechDrug	162394-19-6	Approved	Target
DB01041	Thalidomide	Small Molecule	50-35-1	Approved\|Investigational\|Withdrawn	Target
DB01109	Heparin	Small Molecule	9005-49-6	Approved\|Investigational	Target
DB01901	Sucrosofate	Small Molecule	57680-56-5	Experimental	Target
DB02058	SU4984	Small Molecule		Experimental	Target
DB02491	4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine	Small Molecule		Experimental	Target
DB08896	Regorafenib	Small Molecule	755037-03-7	Approved	Target
DB08901	Ponatinib	Small Molecule	943319-70-8	Approved\|Investigational	Target
DB09078	Lenvatinib	Small Molecule	417716-92-8	Approved\|Investigational	Target
DB09079	Nintedanib	Small Molecule	656247-17-5	Approved	Target

ID	Drug Name	Action	PubMed
C548651	2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester	2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of FGFR2 mRNA	19933214
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of FGFR2 mRNA"	27291303
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of FGFR2 mRNA"	19114083
C013186	2,3-pentanedione	"2,3-pentanedione results in decreased expression of FGFR2 mRNA"	25710175
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of FGFR2 mRNA"	21346803
C023514	2,6-dinitrotoluene	"2,6-dinitrotoluene results in increased expression of FGFR2 mRNA"	20406850
C568950	3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea	"3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea results in decreased activity of FGFR2 protein"	21936542
C023035	3,4,5,3',4'-pentachlorobiphenyl	"3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of FGFR2 mRNA"	23196670
C023035	3,4,5,3',4'-pentachlorobiphenyl	"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of FGFR2 mRNA"	20959002
C561052	5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one	"5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one results in decreased activity of FGFR2 protein"	21608528
D000082	Acetaminophen	Acetaminophen affects the expression of FGFR2 mRNA	25458485
D000082	Acetaminophen	Acetaminophen results in increased expression of FGFR2 mRNA	29067470
D000082	Acetaminophen	[Clofibrate co-treated with Acetaminophen] affects the expression of FGFR2 mRNA	17585979
D000082	Acetaminophen	PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of FGFR2 mRNA]	17585979
D000096	Acetone	Acetone results in increased expression of FGFR2 mRNA	12720008
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of FGFR2 mRNA	22100608
C005277	alpha-naphthyl thiourea	alpha-naphthyl thiourea results in increased expression of FGFR2 mRNA	10755703
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of FGFR2 mRNA	16483693
C006632	arsenic trioxide	arsenic trioxide results in decreased expression of FGFR2 mRNA	15761015
C015001	arsenite	arsenite results in increased methylation of FGFR2 promoter	23974009
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in decreased expression of FGFR2 mRNA"	23634900
D001280	Atrazine	Atrazine results in decreased expression of FGFR2 mRNA	25929836
D001554	Benzene	Benzene results in increased expression of FGFR2 mRNA	15120971\|1512265
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of FGFR2 mRNA"	19150397
D004958	Estradiol	ESR2 protein affects the reaction [Estradiol results in decreased expression of FGFR2 mRNA]	14699072
D004958	Estradiol	Estradiol affects the expression of FGFR2 mRNA	14699072
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in decreased expression of FGFR2 mRNA	20660070
D004958	Estradiol	Estradiol results in decreased expression of FGFR2 mRNA	23019147
D004958	Estradiol	Estradiol results in increased expression of FGFR2 mRNA alternative form	14602803
D004958	Estradiol	Estradiol results in increased expression of FGFR2 protein alternative form	18575591
D004958	Estradiol	ESR1 protein promotes the reaction [Estradiol results in increased expression of FGFR2 mRNA]	25210133
D004958	Estradiol	Estradiol results in increased expression of FGFR2 mRNA	25210133
D004958	Estradiol	Estradiol results in decreased expression of FGFR2 mRNA alternative form	15680359
D004958	Estradiol	Estradiol results in decreased expression of FGFR2 protein alternative form	15680359
C006780	bisphenol A	bisphenol A affects the expression of FGFR2 mRNA	20170705
C006780	bisphenol A	bisphenol A affects the expression of FGFR2 mRNA	26063408
C006780	bisphenol A	bisphenol A affects the expression of FGFR2 mRNA	25181051
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA	25607892
C006780	bisphenol A	bisphenol A results in increased methylation of FGFR2 gene	28505145
D002065	Buspirone	Buspirone results in decreased expression of FGFR2 mRNA	24136188
C027561	butylbenzyl phthalate	butylbenzyl phthalate results in decreased expression of FGFR2 mRNA	26472102
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA	25607892
C487049	BXL628	BXL628 inhibits the reaction [FGF7 protein results in increased phosphorylation of FGFR2 protein]	16289173
D002104	Cadmium	Cadmium results in decreased expression of FGFR2 mRNA	21120746
D002104	Cadmium	Cadmium results in decreased expression of FGFR2 mRNA	22666406
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of FGFR2 mRNA	17484886
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of FGFR2 mRNA	16644059\|1769240
C010063	carbonyl sulfide	carbonyl sulfide results in decreased expression of FGFR2 mRNA	19395590
C084597	chlorcyclizine	chlorcyclizine results in increased expression of FGFR2 mRNA	21058326
D002713	Chlorine	Chlorine results in decreased expression of FGFR2 mRNA	22533443
D004390	Chlorpyrifos	Chlorpyrifos affects the expression of FGFR2 mRNA	18502319
C012843	cinnamic aldehyde	cinnamic aldehyde results in decreased expression of FGFR2 mRNA	17178418
D002994	Clofibrate	[Clofibrate co-treated with Acetaminophen] affects the expression of FGFR2 mRNA	17585979
D002994	Clofibrate	PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of FGFR2 mRNA]	17585979
D003008	Cloprostenol	Cloprostenol results in increased expression of FGFR2 mRNA	14991729
D005576	Colforsin	Colforsin results in increased expression of FGFR2 mRNA	10320526
C007164	cumene hydroperoxide	cumene hydroperoxide results in increased phosphorylation of and results in increased activity of FGFR2 protein	12717419
D003471	Cuprizone	Cuprizone results in increased expression of FGFR2 mRNA	26577399
D003474	Curcumin	Curcumin results in decreased expression of FGFR2 mRNA	15713895
D016572	Cyclosporine	Cyclosporine results in decreased expression of FGFR2 mRNA	27989131
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in increased expression of FGFR2 mRNA	23914054
C014347	decitabine	decitabine results in decreased expression of FGFR2 mRNA	27915011
D003907	Dexamethasone	[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA	16054899
D003907	Dexamethasone	[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
D003907	Dexamethasone	Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
D003907	Dexamethasone	Dexamethasone results in decreased expression of FGFR2 mRNA	20032058
D003907	Dexamethasone	Testosterone inhibits the reaction [Dexamethasone results in decreased expression of FGFR2 mRNA]	20032058
D003975	Diazepam	Diazepam results in decreased expression of FGFR2 mRNA	19114084
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of FGFR2 mRNA	19464577\|2126653
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of FGFR2 protein	26514922\|2891949
D002945	Cisplatin	Cisplatin results in decreased expression of FGFR2 mRNA	21603599
D002945	Cisplatin	FGFR2 protein affects the susceptibility to Cisplatin	16217747
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of FGFR2 mRNA	26472102
C058705	diethyl malate	diethyl malate affects the expression of FGFR2 mRNA	24814887
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of FGFR2 mRNA	24535843
D002117	Calcitriol	Calcitriol results in increased expression of FGFR2 mRNA	21592394
D002117	Calcitriol	Calcitriol results in increased expression of FGFR2 protein	12761878
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of FGFR2 mRNA	21592394
C034171	di-n-pentyl phthalate	di-n-pentyl phthalate results in decreased expression of FGFR2 mRNA	26472102
D004317	Doxorubicin	Doxorubicin affects the expression of FGFR2 mRNA alternative form	15065023
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA	25607892
C010452	estradiol-17 beta-benzoate	estradiol-17 beta-benzoate affects the expression of FGFR2 mRNA	15059950
C074283	estradiol 3-benzoate	estradiol 3-benzoate results in decreased expression of FGFR2 mRNA alternative form	15976484
C074283	estradiol 3-benzoate	[Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of FGFR2 mRNA alternative form	15976484
C024552	estrone benzoate	estrone benzoate results in decreased expression of FGFR2 mRNA alternative form	15120423
D000431	Ethanol	Ethanol results in increased expression of FGFR2 mRNA	12720008
D000431	Ethanol	Ethanol results in decreased expression of FGFR2 protein	16770775
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of FGFR2 mRNA	20170705\|2686566
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of FGFR2 mRNA	18936297
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of FGFR2 mRNA	20170705\|2686566
D005419	Flavonoids	Flavonoids results in increased expression of FGFR2 mRNA	18035473
D005472	Fluorouracil	FGFR2 inhibits the reaction [FGF7 results in decreased susceptibility to Fluorouracil]	18575591
D005472	Fluorouracil	FGFR2 protein alternative form inhibits the reaction [FGF7 protein results in decreased susceptibility to Fluorouracil]	18575591
C006326	fluprostenol	fluprostenol results in decreased expression of FGFR2 mRNA	15654655
D019833	Genistein	ESR2 promotes the reaction [Genistein results in increased expression of FGFR2 protein]	20884965
D019833	Genistein	Genistein results in decreased expression of FGFR2 mRNA	23019147\|2686566
D019833	Genistein	Genistein results in increased expression of FGFR2 protein	20884965
D019307	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]	15654655
D006493	Heparin	[Heparin analog binds to FGFR2 protein alternative form] which binds to and results in increased activity of FGF1 protein	16219767
D006493	Heparin	Heparin promotes the reaction [FGF10 protein binds to FGFR2 protein]	15632068
D006493	Heparin	Heparin affects the activity of FGFR2 protein	1373495
D006493	Heparin	Heparin promotes the reaction [FGFR2 protein binds to FGF2 protein]	1373495
D006493	Heparin	[Heparin binds to FGFR2 protein alternative form] which binds to FGF1 protein	10860838
D006493	Heparin	[Heparin binds to FGFR2 protein alternative form] which binds to FGF2 protein	10860838
D006493	Heparin	[Heparin binds to FGFR2 protein alternative form] which binds to FGF7 protein	10860838
D006493	Heparin	FGF1 protein binds to FGFR2 protein binds to Heparin	15165853\|1622336
D006497	Heparitin Sulfate	Heparitin Sulfate analog results in decreased activity of FGFR2 protein mutant form	16373332
D006497	Heparitin Sulfate	FGF7 protein binds to Heparitin Sulfate binds to FGFR2 protein alternative form	16315317
D006497	Heparitin Sulfate	Heparitin Sulfate analog promotes the reaction [FGF1 protein results in increased activity of FGFR2 protein alternative form]	11714710
D017313	Fenretinide	Fenretinide results in increased expression of FGFR2 mRNA	28973697
D006851	Hydrochloric Acid	Hydrochloric Acid results in increased expression of FGFR2 mRNA	15883737
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of FGFR2 mRNA	20044591
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased expression of FGFR2 mRNA	17997286
D006861	Hydrogen Peroxide	Sodium Selenite promotes the reaction [Hydrogen Peroxide results in decreased expression of FGFR2 mRNA]	17997286
C016517	indole-3-carbinol	indole-3-carbinol affects the expression of FGFR2 mRNA	21396975
D015056	1-Methyl-3-isobutylxanthine	[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA	16054899
D015056	1-Methyl-3-isobutylxanthine	[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
D015056	1-Methyl-3-isobutylxanthine	Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
C533894	LG 100815	LG 100815 results in increased expression of FGFR2 mRNA	16951191
D008044	Linuron	Linuron results in decreased expression of FGFR2 mRNA	12730624
C482199	lipopolysaccharide, E coli O55-B5	"lipopolysaccharide, E coli O55-B5 results in decreased expression of FGFR2 mRNA"	19524256
C042720	mercuric bromide	mercuric bromide results in decreased expression of FGFR2 mRNA	26272509
D008748	Methylcholanthrene	[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of FGFR2 mRNA	23519560
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of FGFR2 mRNA	28001369
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of FGFR2 mRNA	26011545
D008770	Methylnitrosourea	Methylnitrosourea results in increased expression of and affects the localization of FGFR2 protein	15581186
D015735	Mifepristone	Mifepristone results in decreased expression of FGFR2 mRNA	25972201
D009151	Mustard Gas	Mustard Gas affects the expression of FGFR2 mRNA	15651846
D009151	Mustard Gas	Mustard Gas results in decreased expression of FGFR2 mRNA	18988085
C008588	N-(1-naphthyl)ethylenediamine	N-(1-naphthyl)ethylenediamine results in increased expression of FGFR2 mRNA	17311802
C568507	N-(2-(3-(3,5-bis(trifluoromethyl)phenyl)ureido)ethyl)glycyrrhetinamide	"N-(2-(3-(3,5-bis(trifluoromethyl)phenyl)ureido)ethyl)glycyrrhetinamide results in decreased activity of FGFR2 protein"	21888390
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of FGFR2 mRNA"	15585362
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of FGFR2 mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of FGFR2 mRNA"	25554681
C000621033	napabucasin	napabucasin results in decreased expression of FGFR2 mRNA	25605917
C051752	nefazodone	nefazodone results in decreased expression of FGFR2 mRNA	24136188
D009532	Nickel	Nickel results in decreased expression of FGFR2 mRNA	24768652\|2558310
C029938	nickel sulfate	nickel sulfate results in increased expression of FGFR2 protein	12930308
C007350	nitrofen	nitrofen results in decreased expression of FGFR2 mRNA	20638522
C007350	nitrofen	nitrofen results in increased expression of FGFR2 mRNA	21994076
C007350	nitrofen	nitrofen results in increased expression of FGFR2 protein	21994076
D005996	Nitroglycerin	Nitroglycerin results in increased expression of FGFR2 mRNA	12102619
C100284	norgestomet	norgestomet results in decreased expression of FGFR2 mRNA alternative form	10954858
C062198	octa-2,4,6-trienoic acid	"octa-2,4,6-trienoic acid results in increased expression of FGFR2 mRNA"	16951191
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA	25607892
D009844	Oligosaccharides	Oligosaccharides promotes the reaction [FGF1 protein results in increased activity of FGFR2 protein alternative form]	11714710
D009844	Oligosaccharides	Oligosaccharides promotes the reaction [FGF7 protein binds to and results in increased activity of FGFR2 protein alternative form]	11714710
C507134	ON 01910	ON 01910 results in decreased phosphorylation of FGFR2 protein	25472472
C030110	oxaliplatin	oxaliplatin results in increased expression of FGFR2 mRNA	17762391
C030110	oxaliplatin	[oxaliplatin co-treated with Topotecan] results in increased expression of FGFR2 mRNA	25729387
C030110	oxaliplatin	oxaliplatin results in increased expression of FGFR2 mRNA	25729387
D052638	Particulate Matter	Particulate Matter results in decreased expression of FGFR2 mRNA	17987463
D010634	Phenobarbital	[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of FGFR2 mRNA	24535843
D010672	Phenytoin	Phenytoin results in increased expression of FGFR2 mRNA	11352631
D010672	Phenytoin	Phenytoin results in increased expression of FGFR2 protein	11352631
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of FGFR2 mRNA	19710929
C006253	pirinixic acid	pirinixic acid results in decreased expression of FGFR2 mRNA	20813756\|2381119
C006253	pirinixic acid	pirinixic acid results in increased expression of FGFR2 mRNA	18301758
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in decreased expression of FGFR2 mRNA	27989595
C545373	ponatinib	ponatinib analog results in decreased activity of FGFR2 protein	21561767
C545373	ponatinib	ponatinib results in decreased activity of FGFR2 protein	19878872
C545373	ponatinib	ponatinib results in decreased activity of FGFR2 protein mutant form	19878872
C545373	ponatinib	ponatinib results in decreased activity of FGFR2 protein	22238366
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of FGFR2 mRNA	23608068
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in decreased expression of FGFR2 mRNA	20660070
D011374	Progesterone	Progesterone affects the expression of FGFR2 mRNA	17251523
D011374	Progesterone	[Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of FGFR2 mRNA alternative form	15976484
D011374	Progesterone	Progesterone results in decreased expression of FGFR2 mRNA alternative form	15120423
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of FGFR2 mRNA	24780913
D015237	Dinoprost	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]	15654655
D015237	Dinoprost	Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]	16365892
D015237	Dinoprost	Dinoprost affects the localization of FGFR2 protein	15654655
D015237	Dinoprost	Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]	16365892
D015237	Dinoprost	Dinoprost results in decreased expression of FGFR2 mRNA	15654655
D015237	Dinoprost	Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]	15654655
C513428	pyrachlostrobin	pyrachlostrobin results in increased expression of FGFR2 mRNA	27029645
D020849	Raloxifene Hydrochloride	[Raloxifene Hydrochloride co-treated with ESR2 protein] results in decreased expression of FGFR2 mRNA	19059307
D017382	Reactive Oxygen Species	Reactive Oxygen Species results in increased phosphorylation of and results in increased activity of FGFR2 protein	12717419
C052785	rebamipide	rebamipide results in increased expression of FGFR2 mRNA	15104358
C052785	rebamipide	rebamipide results in increased expression of FGFR2 mRNA alternative form	15104358
C089730	rosiglitazone	[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA	16054899
C089730	rosiglitazone	[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
C089730	rosiglitazone	Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of FGFR2 mRNA	25895662
D012822	Silicon Dioxide	Silicon Dioxide results in decreased expression of FGFR2 mRNA	25351596
D012906	Smoke	Smoke results in decreased expression of FGFR2 mRNA	21095227
D018038	Sodium Selenite	Sodium Selenite promotes the reaction [Hydrogen Peroxide results in decreased expression of FGFR2 mRNA]	17997286
C105686	SU 5402	SU 5402 results in decreased activity of FGFR2 protein	21517068
C053081	sucrose octasulfate	sucrose octasulfate binds to FGFR2 protein	15047176
D013498	Suramin	Suramin inhibits the reaction [FGF7 protein binds to FGFR2 protein]	15733146
D014284	Triiodothyronine	Triiodothyronine results in increased expression of FGFR2 mRNA	16150908
D013629	Tamoxifen	FGFR2 inhibits the reaction [FGF7 results in decreased susceptibility to Tamoxifen]	18575591
D013629	Tamoxifen	[Tamoxifen co-treated with ESR2 protein] results in decreased expression of FGFR2 mRNA	19059307
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of FGFR2 mRNA	21592394
D013739	Testosterone	Testosterone results in decreased expression of FGFR2 mRNA	21592394
D013739	Testosterone	Testosterone results in decreased expression of FGFR2 mRNA	7536664
D013739	Testosterone	Testosterone inhibits the reaction [Dexamethasone results in decreased expression of FGFR2 mRNA]	20032058
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of FGFR2 mRNA	23152189
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of FGFR2 mRNA	27913140
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of FGFR2 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with EGF protein] results in decreased expression of FGFR2 mRNA	16054899
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]	16054899
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of FGFR2 mRNA	17586704\|1993321
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of FGFR2 mRNA	16054899
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of FGFR2 mRNA	22298810
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of FGFR2 mRNA	18796159
D013755	Tetradecanoylphorbol Acetate	[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of FGFR2 mRNA	23519560
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]	15654655
D013849	Thimerosal	Thimerosal results in decreased expression of FGFR2 mRNA	27188386
C402769	tipifarnib	tipifarnib results in increased expression of FGFR2 mRNA	16403772
D019772	Topotecan	[oxaliplatin co-treated with Topotecan] results in increased expression of FGFR2 mRNA	25729387
D019772	Topotecan	Topotecan results in increased expression of FGFR2 mRNA	25729387
D014212	Tretinoin	Tretinoin results in decreased expression of FGFR2 mRNA	7680553
D014212	Tretinoin	Tretinoin results in decreased expression of FGFR2 protein	15389522
D014241	Trichloroethylene	Trichloroethylene results in increased methylation of FGFR2 gene	27618143
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of FGFR2 mRNA	19042947
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of FGFR2 mRNA"	26179874
C057693	troglitazone	troglitazone results in decreased expression of FGFR2 mRNA	28973697
D014635	Valproic Acid	Valproic Acid affects the expression of FGFR2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of FGFR2 mRNA	28001369\|2915479
C034028	vanadyl sulfate	vanadyl sulfate results in increased expression of FGFR2 mRNA	16330358
C100058	vanillin	vanillin results in decreased expression of FGFR2 mRNA	17178418
D001335	Vehicle Emissions	Vehicle Emissions results in decreased expression of FGFR2 mRNA	17987463
D024483	Vitamin K 3	Vitamin K 3 affects the expression of FGFR2 mRNA	20044591
C111237	vorinostat	vorinostat results in decreased expression of FGFR2 mRNA	27188386
D014874	Water Pollutants, Chemical	"Water Pollutants, Chemical results in decreased expression of FGFR2 mRNA"	23246600

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004709	MAP kinase kinase kinase activity	-	IBA	21873635
GO:0004713	protein tyrosine kinase activity	-	IBA	21873635
GO:0004713	protein tyrosine kinase activity	-	NAS	1697263
GO:0004713	protein tyrosine kinase activity	-	TAS	-
GO:0004714	transmembrane receptor protein tyrosine kinase activity	-	IBA	21873635
GO:0004888	transmembrane signaling receptor activity	-	IBA	21873635
GO:0005007	fibroblast growth factor-activated receptor activity	-	IDA	8663044 15629145
GO:0005007	fibroblast growth factor-activated receptor activity	-	IGI	10830168
GO:0005007	fibroblast growth factor-activated receptor activity	-	NAS	1400433 1697263 8676562
GO:0005088	Ras guanyl-nucleotide exchange factor activity	-	TAS	-
GO:0005515	protein binding	-	IPI	1309608 10618369 10830168 11390973 12591959 22726438 23597563 25241761 26267536
GO:0005524	ATP binding	-	IEA	-
GO:0008201	heparin binding	-	IEA	-
GO:0016303	1-phosphatidylinositol-3-kinase activity	-	TAS	-
GO:0017134	fibroblast growth factor binding	-	IDA	8663044
GO:0017134	fibroblast growth factor binding	-	IPI	8386828
GO:0031434	mitogen-activated protein kinase kinase binding	-	IBA	21873635
GO:0042803	protein homodimerization activity	-	IPI	16844695
GO:0046934	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000122	negative regulation of transcription by RNA polymerase II	-	ISS	-
GO:0000165	MAPK cascade	-	TAS	-
GO:0001525	angiogenesis	-	ISS	-
GO:0001657	ureteric bud development	-	ISS	-
GO:0001701	in utero embryonic development	-	ISS	-
GO:0001837	epithelial to mesenchymal transition	-	IEA	-
GO:0002053	positive regulation of mesenchymal cell proliferation	-	ISS	-
GO:0003148	outflow tract septum morphogenesis	-	ISS	-
GO:0003149	membranous septum morphogenesis	-	ISS	-
GO:0003416	endochondral bone growth	-	IEA	-
GO:0006915	apoptotic process	-	IEA	-
GO:0007267	cell-cell signaling	-	ISS	-
GO:0007275	multicellular organism development	-	IBA	21873635
GO:0007409	axonogenesis	-	ISS	-
GO:0008284	positive regulation of cell proliferation	-	IBA	21873635
GO:0008284	positive regulation of cell proliferation	-	IDA	8663044
GO:0008284	positive regulation of cell proliferation	-	IGI	8663044
GO:0008284	positive regulation of cell proliferation	-	IMP	15629145
GO:0008543	fibroblast growth factor receptor signaling pathway	-	IDA	8663044 15629145
GO:0008543	fibroblast growth factor receptor signaling pathway	-	IGI	8663044
GO:0008543	fibroblast growth factor receptor signaling pathway	-	IPI	10830168
GO:0008543	fibroblast growth factor receptor signaling pathway	-	TAS	-
GO:0008589	regulation of smoothened signaling pathway	-	ISS	-
GO:0009791	post-embryonic development	-	ISS	-
GO:0009880	embryonic pattern specification	-	ISS	-
GO:0009887	animal organ morphogenesis	-	ISS	-
GO:0009968	negative regulation of signal transduction	-	IBA	21873635
GO:0010453	regulation of cell fate commitment	-	ISS	-
GO:0010518	positive regulation of phospholipase activity	-	IMP	16844695
GO:0016331	morphogenesis of embryonic epithelium	-	ISS	-
GO:0018108	peptidyl-tyrosine phosphorylation	-	IDA	15629145 16844695
GO:0021769	orbitofrontal cortex development	-	ISS	-
GO:0021847	ventricular zone neuroblast division	-	ISS	-
GO:0021860	pyramidal neuron development	-	ISS	-
GO:0022612	gland morphogenesis	-	ISS	-
GO:0030154	cell differentiation	-	IBA	21873635
GO:0030177	positive regulation of Wnt signaling pathway	-	ISS	-
GO:0030282	bone mineralization	-	ISS	-
GO:0030324	lung development	-	ISS	-
GO:0030855	epithelial cell differentiation	-	ISS	-
GO:0030901	midbrain development	-	ISS	-
GO:0030916	otic vesicle formation	-	ISS	-
GO:0031069	hair follicle morphogenesis	-	ISS	-
GO:0032496	response to lipopolysaccharide	-	IEA	-
GO:0032808	lacrimal gland development	-	ISS	-
GO:0033674	positive regulation of kinase activity	-	IBA	21873635
GO:0033688	regulation of osteoblast proliferation	-	TAS	15190072
GO:0035264	multicellular organism growth	-	ISS	-
GO:0035265	organ growth	-	ISS	-
GO:0035602	fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow	-	ISS	-
GO:0035603	fibroblast growth factor receptor signaling pathway involved in hemopoiesis	-	ISS	-
GO:0035604	fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow	-	ISS	-
GO:0035607	fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development	-	ISS	-
GO:0036092	phosphatidylinositol-3-phosphate biosynthetic process	-	IEA	-
GO:0040014	regulation of multicellular organism growth	-	ISS	-
GO:0040036	regulation of fibroblast growth factor receptor signaling pathway	-	ISS	-
GO:0042060	wound healing	-	IEA	-
GO:0042472	inner ear morphogenesis	-	ISS	-
GO:0042476	odontogenesis	-	ISS	-
GO:0043066	negative regulation of apoptotic process	-	IBA	21873635
GO:0043410	positive regulation of MAPK cascade	-	IBA	21873635
GO:0043410	positive regulation of MAPK cascade	-	IMP	15629145
GO:0045165	cell fate commitment	-	ISS	-
GO:0045471	response to ethanol	-	IEA	-
GO:0045667	regulation of osteoblast differentiation	-	TAS	15190072
GO:0045787	positive regulation of cell cycle	-	ISS	-
GO:0045944	positive regulation of transcription by RNA polymerase II	-	ISS	-
GO:0046777	protein autophosphorylation	-	IDA	15629145
GO:0046854	phosphatidylinositol phosphorylation	-	IEA	-
GO:0048286	lung alveolus development	-	ISS	-
GO:0048333	mesodermal cell differentiation	-	IEA	-
GO:0048557	embryonic digestive tract morphogenesis	-	ISS	-
GO:0048562	embryonic organ morphogenesis	-	ISS	-
GO:0048565	digestive tract development	-	ISS	-
GO:0048568	embryonic organ development	-	ISS	-
GO:0048608	reproductive structure development	-	ISS	-
GO:0048661	positive regulation of smooth muscle cell proliferation	-	IEA	-
GO:0048701	embryonic cranial skeleton morphogenesis	-	IMP	7874170 7987400
GO:0048705	skeletal system morphogenesis	-	TAS	15190072
GO:0048730	epidermis morphogenesis	-	ISS	-
GO:0048755	branching morphogenesis of a nerve	-	ISS	-
GO:0048762	mesenchymal cell differentiation	-	ISS	-
GO:0050679	positive regulation of epithelial cell proliferation	-	ISS	-
GO:0050680	negative regulation of epithelial cell proliferation	-	IEA	-
GO:0051150	regulation of smooth muscle cell differentiation	-	ISS	-
GO:0051781	positive regulation of cell division	-	ISS	-
GO:0051897	positive regulation of protein kinase B signaling	-	TAS	-
GO:0055010	ventricular cardiac muscle tissue morphogenesis	-	ISS	-
GO:0060045	positive regulation of cardiac muscle cell proliferation	-	ISS	-
GO:0060174	limb bud formation	-	ISS	-
GO:0060348	bone development	-	ISS	-
GO:0060349	bone morphogenesis	-	ISS	-
GO:0060442	branching involved in prostate gland morphogenesis	-	ISS	-
GO:0060445	branching involved in salivary gland morphogenesis	-	ISS	-
GO:0060449	bud elongation involved in lung branching	-	ISS	-
GO:0060463	lung lobe morphogenesis	-	ISS	-
GO:0060484	lung-associated mesenchyme development	-	ISS	-
GO:0060501	positive regulation of epithelial cell proliferation involved in lung morphogenesis	-	ISS	-
GO:0060512	prostate gland morphogenesis	-	ISS	-
GO:0060523	prostate epithelial cord elongation	-	ISS	-
GO:0060527	prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	-	ISS	-
GO:0060529	squamous basal epithelial stem cell differentiation involved in prostate gland acinus development	-	ISS	-
GO:0060595	fibroblast growth factor receptor signaling pathway involved in mammary gland specification	-	ISS	-
GO:0060601	lateral sprouting from an epithelium	-	ISS	-
GO:0060615	mammary gland bud formation	-	ISS	-
GO:0060664	epithelial cell proliferation involved in salivary gland morphogenesis	-	ISS	-
GO:0060667	branch elongation involved in salivary gland morphogenesis	-	ISS	-
GO:0060670	branching involved in labyrinthine layer morphogenesis	-	ISS	-
GO:0060687	regulation of branching involved in prostate gland morphogenesis	-	ISS	-
GO:0060688	regulation of morphogenesis of a branching structure	-	ISS	-
GO:0060915	mesenchymal cell differentiation involved in lung development	-	ISS	-
GO:0060916	mesenchymal cell proliferation involved in lung development	-	ISS	-
GO:0070372	regulation of ERK1 and ERK2 cascade	-	ISS	-
GO:0070374	positive regulation of ERK1 and ERK2 cascade	-	IBA	21873635
GO:0070374	positive regulation of ERK1 and ERK2 cascade	-	ISS	-
GO:0071300	cellular response to retinoic acid	-	IEA	-
GO:0071560	cellular response to transforming growth factor beta stimulus	-	IEA	-
GO:0090263	positive regulation of canonical Wnt signaling pathway	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005634	nucleus	-	IDA	16597614 17471512
GO:0005654	nucleoplasm	-	IDA	-
GO:0005737	cytoplasm	-	IBA	21873635
GO:0005737	cytoplasm	-	IDA	16597614 17471512
GO:0005794	Golgi apparatus	-	IEA	-
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IBA	21873635
GO:0005887	integral component of plasma membrane	-	IDA	15629145 16844695
GO:0005938	cell cortex	-	IDA	17471512
GO:0009986	cell surface	-	IDA	16597614
GO:0016020	membrane	-	NAS	8676562
GO:0016021	integral component of membrane	-	NAS	1697263
GO:0031012	extracellular matrix	colocalizes_with	IDA	17959718
GO:0031410	cytoplasmic vesicle	-	IEA	-
GO:0043231	intracellular membrane-bounded organelle	-	IDA	-
GO:0043235	receptor complex	-	IBA	21873635
GO:0060076	excitatory synapse	-	ISS	-

KEGG ID	KEGG Term
hsa04010	MAPK signaling pathway
hsa04144	Endocytosis
hsa04810	Regulation of actin cytoskeleton
hsa05200	Pathways in cancer
hsa05215	Prostate cancer

Reactome ID	Reactome Term	Evidence
R-HSA-109704	PI3K Cascade	TAS
R-HSA-112399	IRS-mediated signalling	TAS
R-HSA-1226099	Signaling by FGFR in disease	TAS
R-HSA-1226099	Signaling by FGFR in disease	IEA
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-1643685	Disease	IEA
R-HSA-1839126	FGFR2 mutant receptor activation	TAS
R-HSA-1839126	FGFR2 mutant receptor activation	IEA
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-190241	FGFR2 ligand binding and activation	TAS
R-HSA-190375	FGFR2c ligand binding and activation	TAS
R-HSA-190377	FGFR2b ligand binding and activation	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-2023837	Signaling by FGFR2 amplification mutants	TAS
R-HSA-2033519	Activated point mutants of FGFR2	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-5654221	Phospholipase C-mediated cascade; FGFR2	TAS
R-HSA-5654695	PI-3K cascade:FGFR2	TAS
R-HSA-5654696	Downstream signaling of activated FGFR2	TAS
R-HSA-5654699	SHC-mediated cascade:FGFR2	TAS
R-HSA-5654700	FRS-mediated FGFR2 signaling	TAS
R-HSA-5654727	Negative regulation of FGFR2 signaling	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	IEA
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5663202	Diseases of signal transduction	IEA
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-74751	Insulin receptor signalling cascade	TAS
R-HSA-74752	Signaling by Insulin receptor	TAS
R-HSA-8851708	Signaling by FGFR2 IIIa TM	IEA
R-HSA-8853333	Signaling by FGFR2 fusions	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
20853316	FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. (2011 Aug 1)	Marian C	Int J Cancer
27785367	FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer. (2016 Oct)	Theelen WS	J Pathol Clin Res
25537505	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. (2015 Feb 10)	Kim HS	Oncotarget
29709729	Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy. (2018 Apr 27)	Zanna I	Breast
19212647	FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). (2009 Mar)	Katoh Y	Int J Mol Med
24850843	FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. (2014 Aug 1)	Wang R	Clin Cancer Res
22074045	The FGF and FGFR Gene Family and Risk of Cleft Lip With or Without Cleft Palate. (2013 Jan)	Wang H	Cleft Palate Craniofac J
22768234	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012)	An SJ	PLoS One
22975805	The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov)	Seo JS	Genome Res
19856868	Pfeiffer-like syndrome with holoprosencephaly: a newborn with maternal smoking and alcohol exposure. (2009 Oct)	Su PH	Pediatr Neonatol
27994470	Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data. (2016)	Liu Y	Onco Targets Ther
21791674	Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. (2011 Aug 17)	Campa D	J Natl Cancer Inst